Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control
Portfolio Pulse from Benzinga Newsdesk
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) has presented new preclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The data highlights the benefits of an INTASYL compound targeting CTLA-4 in conjunction with systemic anti-PD-1 antibody therapy. The combination of the INTASYL compound and anti-PD-1 therapy has shown to enhance the efficacy of anti-PD-1 mAb therapy in vivo, eliciting complete regression of ~40% of treated tumors in a mouse model.
November 03, 2023 | 4:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phio Pharmaceuticals' new preclinical data shows potential for its INTASYL compound to enhance tumor control. This could potentially lead to increased investor interest in the company.
The new preclinical data presented by Phio Pharmaceuticals shows the potential of its INTASYL compound to enhance tumor control. This positive news could potentially lead to increased investor interest in the company, which could positively impact the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100